KR20200100726A - 섬유증 치료용 화합물 및 조성물 - Google Patents

섬유증 치료용 화합물 및 조성물 Download PDF

Info

Publication number
KR20200100726A
KR20200100726A KR1020207020574A KR20207020574A KR20200100726A KR 20200100726 A KR20200100726 A KR 20200100726A KR 1020207020574 A KR1020207020574 A KR 1020207020574A KR 20207020574 A KR20207020574 A KR 20207020574A KR 20200100726 A KR20200100726 A KR 20200100726A
Authority
KR
South Korea
Prior art keywords
mkp
group
compound
thio
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207020574A
Other languages
English (en)
Korean (ko)
Inventor
안톤 베넷
조나단 엘만
하야 자말리
카렌 에스. 앤더슨
엘리아스 롤리스
덴튼 호이어
Original Assignee
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예일 유니버시티 filed Critical 예일 유니버시티
Publication of KR20200100726A publication Critical patent/KR20200100726A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
KR1020207020574A 2017-12-18 2018-12-18 섬유증 치료용 화합물 및 조성물 Ceased KR20200100726A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607110P 2017-12-18 2017-12-18
US62/607,110 2017-12-18
PCT/US2018/066191 WO2019126141A1 (en) 2017-12-18 2018-12-18 Compounds and compositions for treating fibrosis

Publications (1)

Publication Number Publication Date
KR20200100726A true KR20200100726A (ko) 2020-08-26

Family

ID=66993802

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020574A Ceased KR20200100726A (ko) 2017-12-18 2018-12-18 섬유증 치료용 화합물 및 조성물

Country Status (9)

Country Link
US (3) US11504373B2 (https=)
EP (1) EP3732179B1 (https=)
JP (2) JP7317039B2 (https=)
KR (1) KR20200100726A (https=)
CN (2) CN116687934A (https=)
AU (3) AU2018388549B2 (https=)
CA (1) CA3085770A1 (https=)
MX (2) MX2020006398A (https=)
WO (1) WO2019126141A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018388549B2 (en) * 2017-12-18 2023-06-01 Yale University Compounds and compositions for treating fibrosis
US12570670B2 (en) * 2019-01-30 2026-03-10 Yale University Compounds, compositions, and methods for treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086859A1 (en) 2000-04-10 2004-05-06 Klaus Ducker Identification of a dual specificity phosphate: dusp-10
DE60125783T2 (de) * 2000-08-11 2007-10-18 Evotec Ag Verfahren zum nachweis von acetylase oder deacetylase-aktivität in einem immunoassay
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP2007518702A (ja) * 2003-11-25 2007-07-12 ノバルティス アクチエンゲゼルシャフト ソマトスタチン類似体処置の効力についてのバイオマーカー
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
EP2351571A4 (en) * 2008-10-09 2012-08-01 Lsip Llc PROTEINPHOSPHATASEHEMMER
CA2944198C (en) 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
AU2018388549B2 (en) * 2017-12-18 2023-06-01 Yale University Compounds and compositions for treating fibrosis

Also Published As

Publication number Publication date
AU2018388549B2 (en) 2023-06-01
JP2021506975A (ja) 2021-02-22
JP2023145544A (ja) 2023-10-11
EP3732179B1 (en) 2024-05-01
EP3732179A1 (en) 2020-11-04
EP3732179A4 (en) 2022-01-19
US20240335445A1 (en) 2024-10-10
CN111670188A (zh) 2020-09-15
AU2023204581A1 (en) 2023-10-05
AU2023204581B2 (en) 2025-06-26
CN116687934A (zh) 2023-09-05
JP7317039B2 (ja) 2023-07-28
US20200390770A1 (en) 2020-12-17
MX2020006398A (es) 2020-09-07
CA3085770A1 (en) 2019-06-27
MX2023009895A (es) 2023-09-04
CN111670188B (zh) 2023-06-23
AU2025234269A1 (en) 2025-10-16
US20230181588A1 (en) 2023-06-15
WO2019126141A1 (en) 2019-06-27
JP7676477B2 (ja) 2025-05-14
US11504373B2 (en) 2022-11-22
AU2018388549A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
EP3849534B1 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
JP2003506388A (ja) 疼痛および不安症を処置または予防するための方法
US20240335445A1 (en) Compounds and Compositions for Treating Fibrosis
MX2007014726A (es) Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
JP2021504314A (ja) Ｍｙｓｔファミリーヒストンアセチルトランスフェラーゼ阻害剤
CN107531683A (zh) Usp7抑制剂化合物及使用方法
CA2813743C (en) Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
WO2022251193A1 (en) Combination therapies
US10442817B2 (en) Inhibitors of RAD52 recombination protein and methods using same
JP2021167301A (ja) Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN108203449A (zh) 一种新型可逆性质子泵抑制剂及其制备方法和用途
EP3881840A1 (en) Sortilin antagonists for use inthe treatment of diabetic retinopathy
HK40098110A (zh) 用於治疗纤维化的化合物和组合物
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
JP2023507188A (ja) 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
WO2025076290A1 (en) 5-6-5/6-bisaryl compounds as flt3 inhibitors
CN104496926B (zh) 一类含二烯四氮唑结构的化合物、其制备方法和用途
JP2002338467A (ja) アデニル酸シクラーゼ５型阻害剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200715

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240419

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D